What we do
Center of Innovation and Preclinical Studies
Quem Somos
About Us
We are located in the innovative environment of the Sapiens Park, in the city of Florianopolis, State of Santa Catarina, Brazil. Sapiens Park comprehends an environment that offers infrastructure and dedicated space to host ventures, projects and other strategic innovative initiatives.
CIEnP has a building area of 5300 m2. (57,000 square feet), with 24 research labs containing modern equipment to carry out efficacy, DMPK and safety non-clinical studies and an area for the incubation of technology-based companies focused on human and animal health.
Pesquisa e Desenvolvimento
News
The next giant step for microbes
Visita ao CIEnP
FDA advisory committee votes for approval of first microbiome-based drug, despite data problems
FDA new drug approvals in Q3 2022
Amylyx’s ALS therapy secures FDA approval, as regulatory flexibility trumps underwhelming data
Nintx and CIEnP partner to develop multi-target therapies against inflammatory bowel diseases
Recursos genéticos de plantas medicinais e fitoterapia: o caso da Lippia
Fresh from the biotech pipeline: too much, too fast?
2021 FDA approvals
Drug pipeline 3Q21—mixed news for genetic therapies
FDA approves AstraZeneca’s anifrolumab for lupus
Drug pipeline 2Q21—accelerated approvals to the fore
FDA new drug approvals in Q2 2021
First approval of a complement C3 inhibitor opens up auto- immune and inflammatory opportunities
FDA approval for Biogen’s aducanumab sparks Alzheimer disease firestorm
Upcoming market catalysts in Q3 2021
Farmacêutica diz à CPI que faturou 8 vezes mais em 2020 com medicamentos do ‘kit Covid’
2020 FDA drug approvals
Drug pipeline 3Q20
FDA approves first BCMA-targeted therapeutic
FDA new drug approvals in Q1 2020
IGF-1R drugs travel from cancer cradle to Graves’
O Centro de Inovação e Estudos Pré-clínicos (CIEnP) ofereceu curso de permeabilidade intestinal in vitro para alunos do MERCOSUL, através da Plataforma Regional de Métodos Alternativos ao Uso de Animais de experimentação (PReMASUL), vinculada ao MCTIC
VISITA AO CIEnP – Dr. Jack L. Arbiser
VISITA AO CIEnP
Anti-CD3 drug keeps diabetes at bay
2019 FDA drug approvals
New Drug Therapy Approvals 2019
Drug pipeline 3Q19
Drug pipeline 3Q19
PARP inhibitor pick- me-up
Centro de Inovação e Estudos Pré-clínicos oferece o II Curso sobre desenvolvimento de medicamentos com foco em estudo não clínico com apoio do Ministério da Saúde e do INCTINOVAMED.
FDA new drug approvals in Q3 2019
Gene therapy successes point to better therapies
Upcoming market catalysts in Q4 2019
Claudin-9 structures reveal mechanism for toxin-induced gut barrier breakdown
Gene therapy’s next installment
FDA new drug approvals in Q2 2019
Pills give patients a shot inside the stomach
Boom: 2018’s biotech IPOs
FDA approves landmark tissue-agnostic cancer drug
Drug pipeline 3Q18
Biopharmaceutical benchmarks 2018
First preventive mAb for hereditary angioedema
FDA new drug approvals in Q3 2018
How much do phase III trials cost?
FDA approves first single-dose antimalarial
PESQUISADORES DO CIEnP MINISTRAM CURSO SOBRE DESENVOLVIMENTO DE MEDICAMENTOS.
US approves first RNA interference drug
FDA new drug approvals in Q2 2018
Golden Rice is safe to eat, says FDA
An FDA perspective on the assessment of proposed biosimilar therapeutic proteins in rheumatology
Statement by FDA Commissioner Scott Gottlieb, M.D., on the importance of conducting proper research to prove safe and effective medical uses for the active chemicals in marijuana and its components
BACE failures lower AD expectations, again
Indian biotech sector readies for liftoff
Drug pipeline: 1Q18
FDA new drug approvals in Q1 2018
New drug for multidrugresistant HIV
FDA approves strokedetecting AI software
Nature Biotechnology’s academic spinouts of 2017
CIEnP realiza minicurso sobre “NONCLINICAL SAFETY EVALUATION”.
Top drugs and companies by sales in 2017
Upcoming market catalysts in Q2 2018
First off-the-shelf mesenchymal stem cell therapy nears European approval
Migraine drug race turns its final corner, FDA decisions in sight
The market for chimeric antigen receptor T cell therapies
Alnylam prepares to land first RNAi drug approval
Secretário geral do Ministério da Ciência, Tecnologia, Inovações e Comunicações e diretor financeiro da FINEP visitaram o CIEnP.
Gene therapies for hemophilia hit the mark in clinical trials
Fresh from the biotech pipeline—2017
FDA warns public of dangers of DIY gene therapy
Top product sales forecasts for 2018
Top product sales forecasts for 2018
Biopharma deal-making in 2017
Innovation in the Amazon
First in vivo gene-editing drugs enter the clinic
Drugmakers cling to dual IL-13/IL-4 blockbuster hop
Texas displays ‘Silicon Valley’ credentials to lure Brazilian biotechs
With a free pass, CRISPR-edited plants reach market in record time
Upcoming market catalysts in Q1 2018
NEWS & ANALYSIS
Top 20 translational researchers of 2016
FDA approves first digital pill
Huntington’s breakthrough may stop disease
Drugs that made headlines in 2017
First Approved Kinase Inhibitor for AML
FDA approves ‘trackable’ pill
Spanish group defeats Shkreli in Chagas voucher race
Predictable response
FDA approves antitoxin antibody
Living therapeutics: Scientists genetically modify bacteria to deliver drugs
Closing the deal
CRISPR therapeutics push into human testing
Innovative academic startups 2016
Top US universities, institutes for life sciences in 2015
PDGFRA Antibody for Soft Tissue Sarcoma
Fresh from the biotech pipeline—2016
Grail to pour $1 billion into blood test to detect early cancer
Nature Biotechnology’s academic spinouts of 2016
Drug pipeline: 4Q16
Novartis trial validates inflammasome as chronic disease driver
Speed and oversight: FDA Commissioner Gottlieb acts on pledges
Epic $12 billion deal and FDA’s approval raise CAR-T to new heights
First metabolic oncology inhibitor gets FDA green light, with record price tag
NIH Centers for Accelerated Innovations Program: principles, practices, successes and challenges
Anti-inflammatory drug cuts risk of heart disease — and cancer
Bispecific antibody pipeline moves beyond oncology
FDA approves first CAR T therapy
CIEnP organiza evento em parceria com a Academia Brasileira de Ciências e EMBRAPII para discutir inovação tecnológica em Fármacos e Medicamentos.
FDA OKs first in vitro route to expanded approval
FDA approves first-in-class cancer metabolism drug
Go-ahead for first anti-IL-23 mAb to treat psoriasis
CRISPR patent estate splinters
FDA OKs first in vitro route to expanded approval
FDA rejects first-in-class osteoporosis drug
Diabetes drug shows promise in Parkinson disease
FDA approves first-in-class cancer metabolism drug
FDA approves first-in-class cancer metabolism drug
FDA approvals for the first 6 months of 2017
Secretário de Ciência, Tecnologia e Insumos Estratégicos do Ministério da Saúde visita o CIEnP
Drug pipeline 2Q17
First eczema biologic debuts but price could restrict use
Genentech’s Ocrevus heralds new chapter in MS treatment
Astex shapes CDK4/6 inhibitor for approval
FDA approves PARP inhibitor for ovarian cancer
Genomics pioneer gets its first drug
Drug pipeline: 1Q17
Academic partnerships 2016
Financing:
Support:
the CIEnP has 24 research labs
and a building area of 5300 m2. (57,000 square feet)
Research and Development
Get Connected
Newsletter!
If you wish to contact the CIEnP call +55 48 3332-8400/8403 or send us an email.
Address
Av. Luiz Boiteux Piazza, 1302 – Florianópolis – SC
contato@cienp.org.br
Phone
+55 (48) 3261-2856